CoChat

Sodium‐glucose co‐transporter‐2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: Anetwork and cumulative meta‐analysis of randomized controlled trials

Tang, Huilin, Li, Dandan, Zhang, Jingjing, Li, Yufeng, Wang, Tiansheng, Zhai, Suodi, Song, Yiqing · 2017 · Diabetes, Obesity and Metabolism
Cited by 71

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Aim: To compare the associations of individual sodium‐glucose co‐transporter ‐ 2 ( SGLT2 ) inhibitors with adverse renal outcomes in patients with type 2 diabetes mellitus ( T2DM ). Methods: PubMed , EMBASE , CENTRAL and ClinicalTrials.gov were searched for studies published up to M ay 24, 2016, without language or date restrictions. Randomized trials that reported at least 1 renal‐related adverse outcome in patients with T2DM treated with SGLT2 inhibitors were included. Pairwise and network meta‐analyses were carried out to calculate the odds ratios ( ORs ) with 95% confidence intervals ( CIs ), and a cumulative meta‐analysis was performed to assess the robustness of evidence. Results: In total, we extracted 1334 composite renal events among 39 741 patients from 58 trials, and 511 acute renal impairment/failure events among 36 716 patients from 53 trials. Dapagliflozin was significantly associated with a greater risk of composite renal events than placebo ( OR 1.64, 95% CI 1.26‐2.13). Empagliflozin seemed to confer a lower risk than placebo ( OR 0.63, 95% CI 0.54‐0.72), canagliflozin ( OR 0.48, 95% CI 0.29‐0.82) and dapagliflozin ( OR 0.38, 95% CI 0.28‐0.51). With regard to acute renal impairment/failure, only empagliflozin was significantly associated with a lower risk than placebo ( OR 0.72, 95% CI 0.60‐0.86). The cumulative meta‐analysis indicated the robustness of our significant findings. Conclusions: The present meta‐analysis indicated that dapagliflozin may increase the risk of adverse renal events, while empagliflozin may have a protective effect among patients with T2DM . Further data from large well‐conducted randomized controlled trials and a real‐world setting are warranted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12917

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 71

Metadata

Authors
Tang, H., Li, D., Zhang, J., Li, Y., Wang, T., Zhai, S., & Song, Y.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2017-03-31
Volume
19
Issue
8
Pages
1106-1115
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2594305555
Cited by
71
References
15
FWCI
8.17
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sodium‐glucose co‐transporter‐2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: Anetwork and cumulative meta‐analysis of randomized controlled trials. https://app.cochat.ai/papers/10.1111/dom.12917
The paper
Tang, H., Li, D., Zhang, J., Li, Y., Wang, T., Zhai, S., & Song, Y. (2017). Sodium‐glucose co‐transporter‐2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: Anetwork and cumulative meta‐analysis of randomized controlled trials. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12917

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.